Gilead Sciences, Inc. (GILD) Return on Equity (ROE): 39.19%
Is Gilead Sciences, Inc.’s return on equity (ROE) high or low?
Gilead Sciences, Inc.'s return on equity (ROE) of 39.19% is 101% above its 5-year average of 19.46%, near the high end of its 5-year range (0.68%–39.19%).
As of Thursday, June 11, 2026. 95.46% above its 12-month average of 20.05%.
GILD Return on Equity (ROE) Chart
GILD Average Return on Equity (ROE) Chart
GILD Current vs Average Return on Equity (ROE) Chart
GILD Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
39.19%
RETURN ON EQUITY (ROE) AVG TTM
20.05%
RETURN ON EQUITY (ROE) AVG 3Y
21.63%
RETURN ON EQUITY (ROE) AVG 5Y
19.46%
RETURN ON EQUITY (ROE) AVG 10Y
32.55%
RETURN ON EQUITY (ROE) AVG 15Y
36.40%
RETURN ON EQUITY (ROE) AVG 20Y
32.29%
CURRENT VS TTM AVG
+95.46%
CURRENT VS 3Y AVG
+81.16%
CURRENT VS 5Y AVG
+101.39%
CURRENT VS 10Y AVG
+20.42%
CURRENT VS 15Y AVG
+7.66%
CURRENT VS 20Y AVG
+21.35%
GILD Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $156.35B | 39.19% | 20.05% | 21.63% | 19.46% |
| Abbott Laboratories (ABT) | $155.75B | 12.06% | 20.32% | 18.59% | 17.97% |
| Pfizer Inc. (PFE) | $149.61B | 8.31% | 9.04% | 13.32% | 16.07% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 17.05% | 15.07% | 13.91% | 13.46% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 13.21% | 12.70% | 13.51% | 15.24% |
| CVS Health Corporation (CVS) | $126.70B | 3.79% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR) | $126.39B | 6.97% | 7.38% | 9.51% | 10.24% |
| Amgen Inc. (AMGN) | $188.37B | 84.87% | 79.33% | 111.35% | 101.76% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 36.25% | -8.30% | 7.76% | 4.45% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 22.41% | 8.96% | 15.60% | 19.47% |
Return Analysis
ROE
39.2%
ROA
16.4%
Gilead Sciences, Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The return on equity (ROE) for GILD stock is 39.19%.
- Is Gilead Sciences, Inc.'s return on equity (ROE) high or low?
- Gilead Sciences, Inc.'s return on equity (ROE) of 39.19% is 101% above its 5-year average of 19.46%, near the high end of its 5-year range (0.68%–39.19%).
- What is the TTM average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The TTM average return on equity (ROE) for GILD stock is 20.05%.
- What is the 3Y average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The 3Y average return on equity (ROE) for GILD stock is 21.63%.
- What is the 5Y average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The 5Y average return on equity (ROE) for GILD stock is 19.46%.
- What is the 10Y average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The 10Y average return on equity (ROE) for GILD stock is 32.55%.
- What is the 15Y average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The 15Y average return on equity (ROE) for GILD stock is 36.40%.
- What is the 20Y average return on equity (ROE) for Gilead Sciences, Inc. (GILD)?
- The 20Y average return on equity (ROE) for GILD stock is 32.29%.
Gilead Sciences, Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 37.62% |
| 2024-12-31 | 2.48% |
| 2023-12-31 | 24.81% |
| 2022-12-31 | 21.62% |
| 2021-12-31 | 29.55% |
| 2020-12-31 | 0.68% |
| 2019-12-31 | 23.91% |
| 2018-12-31 | 25.51% |
| 2017-12-31 | 22.64% |
| 2016-12-31 | 71.48% |
| 2015-12-31 | 97.70% |
| 2014-12-31 | 78.45% |
| 2013-12-31 | 27.04% |
| 2012-12-31 | 27.86% |
| 2011-12-31 | 41.60% |
| 2010-12-31 | 49.48% |
| 2009-12-31 | 41.40% |
| 2008-12-31 | 46.32% |
| 2007-12-31 | 46.69% |
| 2006-12-31 | -65.54% |
| 2005-12-31 | 26.88% |
| 2004-12-31 | 24.02% |
| 2003-12-31 | -7.18% |
| 2002-12-31 | 12.62% |
| 2001-12-31 | 11.55% |
| 2000-12-31 | -16.17% |
| 1999-12-31 | -22.37% |
| 1998-12-31 | -13.43% |
| 1997-12-31 | -22.98% |
| 1996-12-31 | -7.44% |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day